Filing Flows › Beta Bionics (BBNX) › R&D spending
Beta Bionics (BBNX) R&D spending by quarter
Beta Bionics' R&D spending was $12.0M in Q3 2026 (third quarter 2026), +17% from Q2 2026. Over the last 7 quarters it ranged from $7.6M (Q1 2025) to $12.0M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $12.0M | +17% | +46% |
| Q2 2026 | $10.2M | -1% | +15% |
| Q1 2026 | $10.4M | +2% | +36% |
| Q4 2025 | $10.1M | +24% | — |
| Q3 2025 | $8.2M | -8% | — |
| Q2 2025 | $8.9M | +17% | — |
| Q1 2025 | $7.6M | — | — |
Q3 2026 at a glance
Beta Bionics, Q3 2026: revenue $35.5M (+30% year over year), operating margin -74.9%, net loss $24.4M, operating cash flow −$12.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Beta Bionics' R&D spending?
Beta Bionics' R&D spending was $12.0M in Q3 2026 (third quarter 2026), +17% from Q2 2026.
How has Beta Bionics' R&D spending changed?
Over the last 7 quarters it ranged from $7.6M (Q1 2025) to $12.0M (Q3 2026).